Interim report 1 January - 30 June 1999

Interim report 1 January - 30 June 1999 @ Medivir buys back MIV-606 shingles drug @ Phase II studies of ME-609 herpes cream have started @ HIV drug MIV-150 approved for clinical phase I trials @ Profit after financial items of 28.5 MSEK (-15.0 MSEK) ------------------------------------------------------------ Please visit for further information The following files are available for download: The full report The full report

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.